Login

Forgot password?
Sign up today and your first download is free.
REGISTER

Opioids

February 27, 2019 | Daily News

House Energy & Commerce ranking Republican Greg Walden (OR) will speak with FDA Commissioner Scott Gottlieb about marijuana-related issues as part of a regular meeting the congressman has with the agency head, Walden told Inside Health Policy after speaking at an event at the American Enterprise Institute.

February 22, 2019 | Daily News

HHS Secretary Alex Azar highlighted the administration’s efforts to lower drug prices at the top of his State of the Department speech Friday (Feb. 22), though his half-hour presentation covered a broad range of initiatives and accomplishments.

February 21, 2019 | Daily News

West Virginia’s senators are asking lawmakers to support them in pushing HHS to align the strict privacy scheme for substance abuse treatment records with the looser Health Insurance Portability and Accountability Act (HIPAA), echoing the calls of physician and hospital groups.

February 21, 2019 | Daily News

Physician and hospital groups called for aligning the strict privacy scheme that requires explicit patient consent to share substance abuse treatment records with the more lax Health Insurance Portability and Accountability Act (HIPAA) standards, as well as for fewer regulations, in response to the HHS Office of Civil Rights’ (OCR) request for feedback on how HIPAA might be getting in the way of value-based care.

February 13, 2019 | Daily News

A coalition of organizations focused on health care, public health and safety, drug diversion prevention, and drug abuse prevention and treatment, and a former congresswoman, wrote to FDA Commissioner Scott Gottlieb urging the agency to embrace innovative, at-home systems for disposal of drugs when it implements wide-ranging legislation passed last year as part of congressional efforts to curb the opioid crisis.

February 07, 2019 | Daily News

The Senate health committee will hold a hearing next Tuesday (Feb. 12) to discuss progress in developing non-addictive pain therapies, how health care providers can better treat pain patients and potential federal barriers to improving care for people with pain.

February 06, 2019 | Daily News

FDA on Wednesday (Feb. 6) finalized guidance detailing the types of clinical studies and novel endpoints that can be used to support approval of depot buprenorphine products and how sponsors should design efficacy trials.

January 23, 2019 | Daily News

Health IT Now said at a briefing on Tuesday (Jan. 22) that it will focus on modernizing the Health Insurance Portability and Accountability Act (HIPAA) in 2019 -- though the group will not say what that entails -- and aligning the stricter 42 CFR Part 2 privacy with a revamped version of HIPAA.

January 18, 2019 | Daily News

In an effort to encourage drug companies to develop over-the-counter (OTC) versions of overdose-reversal drug naloxone, FDA has developed a model drug facts label with pictograms that show how to use the drug, which can help consumers better understand how to use naloxone without the supervision of a health care professional, agency chief Scott Gottlieb announced on Thursday (Jan. 17).

January 17, 2019 | Daily News

Federal Medicare advisers grappled Thursday (Jan. 17) with how CMS could better track opioid use in hospitals and encourage non-opioid alternatives, and it must report to Congress on those issues by March due to a mandate in last year’s landmark opioid bill.

December 05, 2018 | Daily News

The Institute for Clinical Economic Review (ICER) on Monday (Dec. 3) issued a final report featuring recommendations for how to develop policy on and increase access to extended-release medications for addiction treatment.

November 30, 2018 | Daily News

After six months and over 250 applications, FDA finally announced the eight winners of an innovation challenge in which medical device developers submitted to the agency their best ideas for preventing and treating opioid addiction.

November 21, 2018 | Daily News

As pharmacy and other health care stakeholders convened last week to discuss myriad issues surrounding illegal online sales of prescription drugs, one FDA official called for companies that manage and sell internet domain names to ramp up enforcement of their terms of use agreements and stop allowing violative website operators to continue leasing domains under different website names. This, the official said, would help fix the whack-a-mole issue on FDA’s side of enforcement.

November 19, 2018 | Daily News

Kaleo CEO Spencer Williamson offered to lower the $4,100 price of the opioid overdose reversal drug Evzio as long as insurers give patients greater access to it, during his appearance on CBS’ “60 Minutes” on Sunday.

November 15, 2018 | Daily News

FDA Commissioner Scott Gottlieb tried to assure a National Academies of Sciences, Engineering and Medicine (NASEM) committee that while the agency plans to develop and publish prescribing guidelines for acute pain, the agency does not intend to regulate the practice of medicine.

November 13, 2018 | Daily News

CMS will give states more leeway to cover inpatient treatment for serious mental illnesses, just as the agency has been doing for inpatient treatment of substance use disorders, HHS Secretary Alex Azar announced Tuesday (Nov. 13).

November 13, 2018 | Daily News

A leading public health advocate official is hopeful the incoming Democratic-led House will investigate FDA’s controversial approval of the sufentanil drug DSUVIA.

November 07, 2018 |

With Democrats taking control of the House, Rep. Frank Pallone (D-NJ) is highly expected to chair the powerful Energy & Commerce Committee, and, although he comes from a pharmaceutical-heavy district, he told Inside Health Policy prior to the election results that tackling high drug prices would be a top priority as would overseeing the administration's health care agenda.

November 07, 2018 | Daily News

With Democrats taking control of the House, Rep. Frank Pallone (D-NJ) is highly expected to chair the powerful Energy & Commerce Committee, and, although he comes from a pharmaceutical-heavy district, he told Inside Health Policy prior to the election results that tackling high drug prices would be a top priority as would overseeing the administration's health care agenda.

November 07, 2018 | Daily News

With a Democratic takeover of the House, the powerful Energy & Commerce Committee will experience leadership and priority shifts. A former congressional aide told Inside Health Policy that Democrats may use the opportunity to push the Creating and Restoring Access to Equivalent Samples (CREATES) Act, seek funding options for opioid-related initiatives, focus more on cosmetics legislation and revisit laboratory-developed test (LDT) legislation.

Pages